Neurocritical Care News

A nonprofit focused on treatments and cures for Charcot-Marie-Tooth disease will partner with a biotechnology firm to advance a novel intrathecal miRNA therapy to address CMT type 1a in adults with the condition.

The American Brain Foundation has announced the launch of a $10 million cross-disciplinary research initiative for neuroscientists to investigate the role of neuroinflammation in a wide range of neurologic and psychiatric brain diseases.

The FDA has cleared an investigational new drug application for AVB-101 to treat those with frontotemporal dementia with mutations in the progranulin gene, according to a release from the manufacturer.

Nido Biosciences has announced positive results from a phase 1 study of its novel, small molecule therapeutic to treat spinal and bulbar muscular atrophy in healthy male participants.

A Bay Area neurotechnology firm has announced the commercial release of a novel artificial intelligence-based software algorithm that continuously monitors brain activity of those with electrographic status epilepticus.

The FDA has approved a 40 mg/mL oral suspension of Agamree to treat Duchenne muscular dystrophy in patients aged 2 years and older, according to a release from the manufacturer.

Compared with placebo, donanemab slowed disease progression and reduced amyloid presence at 76 weeks for carriers and noncarriers of the APOE ε4 allele in early symptomatic Alzheimer’s disease, according to data presented at CTAD.

Beckley Psytech announced dosing of the first patient in a phase 2b clinical trial of BPL-003, an intranasal synthetic formulation of the psychedelic compound 5-MeO-DMT for treatment-resistant depression.

Ecopipam, a novel investigational compound for central nervous system disorders significantly reduced symptoms of Tourette syndrome in a cohort of pediatric patients, according to the manufacturer.

For individuals exposed to athletic-related head contact, glial fibrillary acidic protein may help identify those who are at risk for progressive regional brain atrophy and cognitive decline, per data from Alzheimer’s Research & Therapy.